VistaGen Therapeutics Company Presentation

www.vistagen.com 17 PH94B for Acute Treatment of SAD in the U.S. SUBSTANTIAL UNMET NEED DIFFERENTIATED SAFETY vs. BENZOS STRONG INTENT TO PRESCRIBE RAPID-ONSET MOA ~$2.17B - $3.1B* potential commercial opportunity for PH94B in U.S. SAD market * Includes pediatric SAD indication, peak year sales; but excludes all other anxiety-related disorders ; market research and commercial assessment prepared by i3 Strategy, Winter 2019